Instrument NameHims & Hers Health IncInstrument Symbol(HIMS-N)

Instrument ExchangeNYSE

Buying a new pharmacy will allow Hims & Hers to expand into new markets.

Telemedicine once seemed like it was going to revolutionize healthcare.

The healthcare company will be making more of the product it sells.

Shares of Hims & Hers are falling even as the company has been posting some solid results.

Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.

The risk-reward proposition is pretty one-sided here.

Lilly just lowered the price of Zepbound.

There is something for everybody in America's $4.5 trillion healthcare market.

Sales growth could accelerate now that it provides lower-cost, weight-management drugs.

These businesses are rapidly growing profits and cash flows.

A new threat from Eli Lilly pushed the stock lower.

The stock has been a strong performer this year, but the best could be yet to come.

Could a competitor lowering prices eat into Hims & Hers market share?

After a strong start to the year, the stock is down 30% since June.

These companies aren't slowing down.

Wall Street is missing the forest for the trees, and the opportunity is enormous.

A small telemedicine company just entered the weight loss race.

A company's investments can easily ruin the plans of its competitors.

Growth is set to accelerate starting next quarter, powered by its GLP-1 offering.

Don't overlook the 52% growth in the second quarter.

Hims & Hers stock has been surging since May, but has its valuation gotten too rich?

Even a modest investment can help you start a position in quality stocks.

Hims & Hers shares have multi-bagger growth potential over the years to come.

Price is just one factor to consider.

It wasn't easy to double in 2024, but these three stocks made it happen. They might be able to do it again.